Maximising the impact of KET Biotechnology - Chassychassy.eu/media/2012/12/Maximising-Impact-of-KET-Biotechnology.pdf · The 2016 workshop “Maximising the impact of KET Biotechnology”

Rapporteur Monica Garcia-Alonso

EN

Maximising the impact of KET

Biotechnology

Workshop Report

Brussels 15-16 November 2016

EUROPEAN COMMISSION

Directorate-General for Research and Innovation

Directorate D mdash Industrial Technologies

Unit D2 mdash Advanced Manufacturing Systems and Biotechnologies

Contact Ioannis Vouldis

E-mail IoannisVouldiseceuropaeu

RTD-PUBLICATIONSeceuropaeu

European Commission

B-1049 Brussels

EUROPEAN COMMISSION


Biotechnology

Workshop Report


Rapporteur

Monica Garcia-Alonso


2017 Key Enabling Technologies EN

LEGAL NOTICE

This document has been prepared for the European Commission however it reflects the views only of the authors and the Commission cannot be held responsible for any use which may be made of the information contained therein More information on the European Union is available on the internet (httpeuropaeu)

Luxembourg Publications Office of the European Union 2017

PDF ISBN 978-92-79-63555-7 doi 10277769039 KI-05-16-025-EN-N

copy European Union 2017

Reproduction is authorised provided the source is acknowledged

EUROPE DIRECT is a service to help you find answers

to your questions about the European Union

Freephone number ()

00 800 6 7 8 9 10 11

() The information given is free as are most calls (though some operators phone boxes or hotels may charge you)

4

CONTENTS

EXECUTIVE SUMMARY 5

1 AGENDA OF THE WORKSHOP 6

2 INTRODUCTION 6

3 HORIZON 2020 PRESENTATIONS 7

31 Cutting edge biotechnologies 9

32 Biotechnology-based industrial processes 13

33 Innovative platform technologies 17

34 Cross-cutting biotechnology actions 19

35 SME Instrument 20

4 CHALLENGES IN BIOTECHNOLOGY 21

41 Industryrsquos point of view 21

42 Academiarsquos point of view 22

43 Standardisation of biological components and databases 23

5 INTERNATIONAL DIMENSION OF BIOTECHNOLOGIES 23

51 Biotechnology in the USA 23

52 Biotechnology in China 24

53 Biotechnology in South Korea 25

54 Biotechnology in Japan 26

6 PANEL DEBATE 27

7 CONCLUSIONS 29

Appendix 1 Agenda 30

Appendix 2 List of participants 32

Appendix 3 List of abbreviations 32

5

EXECUTIVE SUMMARY

In line with the goals of Open Innovation Open Science and Open to the World the European

Commission organised a second Workshop on ldquoMaximising the Impact of KET Biotechnologyrdquo The

workshop took place in Brussels on 15 and 16 November 2016 It discussed ongoing European

research and innovation biotechnology projects and their future added value

The workshop gathered a range of academic and industrial project beneficiaries representing 21

KET Biotechnology projects funded through Horizon 2020 representatives from the European

Association for Bio-industries (EuropaBio) and the European Federation of Biotechnology (EFB)

delegates from jurisdictions leading in biotechnology (USA China Korea and Japan) an expert on

standardisation in synthetic biology representatives of the Bio-based Industries Joint Undertaking

and representatives of the European Commission

In Horizon 20201 to date 17 projects have received funding through the RIA (Research and

Innovation Action) and the IA (Innovation Action) schemes An additional project is supported as a

Coordinated and Support Action (CSA) and another project through the ERA-NET Cofund scheme

an approach that aims to support Public-Public Partnerships These projects focus on three

thematic areas under the specific objective Leadership in Enabling and Industrial Technologies

(LEIT)2 KET Biotechnology also funds projects through the SME instrument that offers business

innovation support to Small and Medium-sized Enterprises

The event provided an opportunity for project partners concerned to show actual and potential

progress towards expected impacts A diversity of scientific industrial and market difficulties and

challenges in modern biotechnology emerged Stakeholders set out the opportunities challenges

and bottlenecks of biotechnologies in Europe both from an industrial and academic perspective

International speakers outlined the history state of the art and interests in industrial biotechnology

in their countries as a way to level out potential cooperation with Europe The panel debate focused

on improving the exploitation of project results and on positive experiences of cooperation to

enhance success

The discussion of the impact at the workshop focused on the following key aspects 1) successes

(patents prototypes publications new business opportunities) difficulties and good practices for

maximising impact plus explored common interests for collaboration among projects and beyond

the projects framework 2) building capacities for a new generation of researchers interested in

closing the gap to market new products new processes and new services beyond the originally

expected patents and publications and even interested in scaling up a business activity through

SMEs 3) need for supportive public policies for industrial biotechnology that would facilitate the

transfer from research products to the market and 4) the identification of standardisation of

synthetic biology as a driver of the fourth industrial revolution and a must to keep a leadership role

in Europe

1Horizon 2020 the European Unions Framework Programme for Research amp Innovation (2014-2020)

2(i) Boosting cutting-edge biotechnologies as future innovation drivers (ii) Biotechnology-based industrial

products and processes (iii) Innovative and competitive platform technologies

6

1 AGENDA OF THE WORKSHOP

The 2016 workshop ldquoMaximising the impact of KET Biotechnologyrdquo was the second of its kind

organised by the Directorate General for Research and Innovation (RTD) of the European

Commission (EC) The workshop took place on 15 and 16 November 2016 at the premises of the

Committee of the Regions in Brussels Belgium and was attended by 50 participants from a range

of stakeholder groups including among others project partners academia and industry

representatives and international delegates

The workshop was divided into six sessions

1 Introduction

2 Horizon 2020 project presentations

3 Challenges in biotechnology

4 International dimension of biotechnologies

5 Panel discussion on maximising the impact of KET Biotechnology

6 Conclusions

2 INTRODUCTION

Mr Jose-Lorenzo Valles (Head of Unit Advanced Manufacturing Systems and Biotechnologies RTD)

opened the workshop introduced the agenda and outlined the main objectives of the event He

highlighted the importance of exchanging information and good practices as well as networking

and clustering opportunities both within and among projects and from international participants

Mr Peter Droumlll (Director Industrial Technologies RTD) welcomed the participants and stressed

the role of Industrial Biotechnology as one of the EUs strengths He stated that Biotechnology as a

Key Enabling Technology is a major driving force for EU innovation which has clear potential to

boost competition Mr Droumlll summarised the biotechnology grants agreements funded since the

inception of Horizon 2020 (19 large projects and 38 small projects through the SME instrument) for

an amount of over euro150 million He recalled the launch of the ERA-NET CoBioTech with a total

budget of approximately euro363 million (of which euro10 million comes from the Horizon 2020 budget)

where 18 countries inside and outside the EU will participate in the co-funded call He also

highlighted that euro56 million would be distributed to successful proposals under the 2017 call

funding research for the reuse of CO2 the use of new plant breeding techniques the optimisation

of biocatalysis plus the support to biotechnology SMEs Mr Droumlll referred to the work under

preparation for the last Work Programme of Horizon 2020 (2018-2020) and the significance of

aligning to major EU policy objectives in particular to the energy and climate actions Mr Droumlll

addressed the four international speakers highlighting the importance of global scientific

collaboration at a time when we share major challenges Mr Droumlll concluded with some words for

the SMEs in particular for those participants representing projects funded through the SME

Instrument commending their role filling the gap from laboratory to market and invited everyone

to convert innovative ideas into new products services or businesses

The workshop continued with presentations from each of the 21 projects present The first 17

presentations were from projects funded as RIA or IA actions through calls under one of the three

7

thematic areas previously described (footnote in page 5) These included three sets of project

presentations One set was composed of the Cutting-edge Biotechnologies projects on synthetic

biology (Mycosynvac Empowerputida and P4SB) and systems biology (Topcapi Chassy and

Rafts4Biotech) The second set included projects under the theme Biotechnology-based Industrial

Processes either for downstream processing (DiViNe and nextBioPharmDSP) biocatalysis (Robox

and CarbaZymes) or focusing on bioconversion of waste (Volatile Falcon and Dafia) In the third

set there were presentations from projects framed as ldquoInnovative Platformsrdquo in bioinformatics (DD-

DeCaF and CanPathPro) and metagenomics (Metafluidics and Virus-X) In addition two

presentations were made of crosscutting actions the ERA-NET Cofund CoBioTech and the

CommunitySupport Action Progress followed by presentations of the two projects funded through

the SME Instrument (SO2SAFE and APEX) The first day ended with a networking activity

On the 16 November the workshop continued with a session about ldquoChallenges in Biotechnologyrdquo

with speakers from industry and academia who shared their views on the challenges needs and

opportunities of biotechnology in the EU A thematic presentation underlined the importance of

standardisation of biological components with the focus put on synthetic biology The next session

was on the ldquoInternational Dimensions of Biotechnologiesrdquo with presentations from speakers from

the USA China South Korea and Japan providing the global dimension of the workshop The main

areas of research funded in their countries were introduced and the importance of cooperation was

emphasised to keep up to date with and be able to meet the challenges faced by modern society

The workshop concluded with a debate during which invited panelists from a small and a large

company a representative each from DG GROW EASME and the BBI Joint Undertaking contributed

their reflections as a basis for a discussion with the audience The rapporteur Mrs Monica Garcia-

Alonso summarised the main highlights of the workshop and the chair Mr Jose-Lorenzo Valles

closed it

3 HORIZON 2020 PRESENTATIONS

This section summarises the participation of the Horizon 2020 funded Biotechnology projects in the

workshop Biotechnology is one of the Key Enabling Technologies (KET) that have the potential of

strengthening the EUrsquos industrial and innovation capacity while addressing societal challenges (SC)

such as health demographic change and wellbeing (SC1) food security sustainable agriculture

and forestry marine and maritime and inland water research and the Bioeconomy (SC2) secure

clean and efficient energy (SC3) and climate action environment resource efficiency and raw

materials (SC5)

The Workshop 2016 gathered the seven RIA and IA Horizon 2020 projects that already participated

in the first workshop (2015) 12 new projects funded in 2016 (10 RIA 1 CSA 1 ERA-NET) and two

projects funded by the SME Instrument Projects that received funding after selection from the

2014-2015 Work Programme calls for proposals had been underway for about 18 months or 6

months respectively other projects selected in the call for the first year of the 2016-2017 Work

Programme were just starting at the time of the workshop

The 2014 Horizon 2020 call for proposals in Biotechnology included three topics (BIOTEC-01-2014

BIOTEC-03-2014 and BIOTEC-04-2014) (Box 1) In this call seven proposals were funded with a

total budget of around EUR 54 million

8

The 2015 Horizon 2020 call for proposals in Biotechnology included two topics (BIOTEC-02-2015

and BIOTEC-06-2015) (Box 1) Out of the proposals received four proposals were funded with a

total budget of around euro34 million In addition 38 Biotechnology projects have been funded to

date under the SME instrument (BIOTEC-05-201415 and BIOTEC-03-20162017) with a budget of

almost euro16 million

Box 1 Horizon 2020 Work Programme 2014-2015 in Biotechnology3 topics and projects

BIOTEC-01-2014 Synthetic biology minus construction of organisms for new products and

processes (RIA) Mycosynvac Empowerputida P4SB

BIOTEC-02-2015 New bioinformatics approaches in service of biotechnology (RIA)

DD-DeCaF CanPathPro

BIOTEC-03-2014 Widening industrial applications of enzymatic processes (IA)

Robox Carbazymes

BIOTEC-04-2014 Downstream processes unlocking biotechnological transformations (IA)

Divine nextBiopharmDSP

BIOTEC-05-201415 SME-boosting biotechnological-based industrial processes driving competitiveness and sustainability (SME instrument) SO2SAFE APEX BIOTEC-06-2015 Metagenomics as innovation driver (RIA) Metafluidics Virus-X

Regarding the Work Programme 2016-2017 on Biotechnology eight projects were selected in the

2016 call that included four topics (BIOTEC-01-2016 BIOTEC-02-2016 BIOTEC-03-2016 and BIOTEC-

04-2016) (Box 2) and were funded with a budget of about euro 47 million

The 2017 Horizon 2020 Work Programme in Biotechnology was composed of four topics (BIOTEC-05-

2017 BIOTEC-06-2017 BIOTEC-07-2017 and BIOTEC-08-2017) The submission of pre-proposals to

topics with two evaluation stages ended shortly before the workshop (27 October 2016) The

outcome of the second stage evaluation will be known early summer 2017 and projects might start

before the year-end The call for the topic BIOTEC-08-2017 opened only on 20 September 2016

3 httpseceuropaeuresearchparticipantsdatarefh2020wp2014_2015mainh2020-wp1415-leit-nmp_enpdf

9


BIOTEC-01-2016 ERA-NET Cofund on Biotechnologies CoBioTech

BIOTEC-02-2016 Bioconversion of non-agricultural waste into biomolecules for industrial

applications (RIA) Dafia Falcon Volatile

BIOTEC-03-2016 Microbial chassis platform with optimised metabolic pathways for industrial

innovations through systems biology (RIA) Topcapi Chassy Rafts4Biotech

BIOTEC-04-2016 KET Biotechnology foresight identifying gaps and high-value opportunities for

the EU industry (CSA) Progress

BIOTEC-05-2017 Microbial platforms for CO2-reuse processes in the low-carbon economy (RIA)

project(s) tba

BIOTEC-06-2017 Optimisation of biocatalysis and downstream processing for the sustainable

production of high value-added platform chemicals (IA) project(s) tbd

BIOTEC-07-2017 New Plant Breeding Techniques (NPTB) in molecular farming Multipurpose

crops for industrial bioproducts (RIA) project(s) tbd

BIOTEC-08-2017 Support for enhancing and demonstrating the impact of KET Biotechnology

projects (CSA) project(s) tbd

31 Cutting edge biotechnologies

Mycosynvac

Engineering of Mycoplasma pneumoniae as a broad-spectrum

animal vaccine

No effective vaccination exists against many mycoplasmas that infect domestic animals causing

respiratory disorders that are regarded as being among the most serious disease problems in

modern production systems With a combination of systems biology whole cell modelling and

modern tools of synthetic biology Mycosynvac engineers Mycoplasma pneumoniae to make it a

universal chassis for vaccination The significance of the objectives of this project is based on the

fact that the global veterinary vaccines market which was $6 billion in 2013 is expected to total

$9 billion by 2020

4 httpeceuropaeuresearchparticipantsdatarefh2020wp2016_2017mainh2020-wp1617-leit-nmp_enpdf

10

Mycosynvacrsquo efforts to maximise impact focus on (1) having a clear target (2) relying on key

industrial partners within the consortium both for developing and exploiting vaccines and for

technology development (3) identifying key objectives at the very start of the project in terms of

the vaccine chassis the necessary experimental conditions and the target hosts (4) developing a

credible exploitation plan that also (5) considers different business models for results other than

vaccines The role of the ldquoInnovation Boardrdquo composed of the industries and technology transfer

specialists from academic partners is also essential to identify new opportunities for exploitation of

research results Biodiversity-sensitive epitope mapping involving the development of a

technology was shown as one of these examples

Project starting year 2015

Project reference 634942

Coordinator Fundacioacute Centre de Regulacioacute Genoacutemica (Spain)

Website wwwmycosynvaceu

EmPowerPutida

Exploiting native endowments by re-factoring re-programming

and implementing novel control loops in Pseudomonas putida for

bespoke biocatalysis

EmPowerPutida aims to engineer the lifestyle of Pseudomonas putida to obtain a tailored re-

factored chassis for the production of so far non-accessible biological compounds Based on the

outstanding metabolic endowment and stress tolerance capabilities of P putida the project uses

mathematical models user-friendly design software and modern tools of synthetic biology to

enhance replace and remove the necessary traits to make a versatile chassis capable of

generating scores of chemicals and products with an exceptional efficiency The two showcase

products are two biofuel molecules (n-butanol and isobutanol and their gaseous derivatives 1-

butene and (iso-)butadiene) and an active ingredient tabtoxin a high-value szlig-lactam-based

secondary metabolite as a new herbicide

In order to maximise impact for each of these classes of products Empowerputida relies on

leading industrial companies that participate in the project and are ready to develop these

technologies further If successful the project is guided by a roadmap starting from an identified

set of exploitable results that foresees industrial production and commercialisation of the target

chemicals in about five to seven years after the project completion



Coordinator Wageningen University (The Netherlands)

Website httpwwwempowerputidaeu

11

P4SB

From Plastic waste to Plastic value using Pseudomonas putida

Synthetic Biology

The objective of P4SB is the biotransformation of non-sustainable oil-based plastic waste into

sustainable value-added alternative materials with the use of tools of synthetic biology With these

tools new enzymes will bio-depolymerise two types of plastic PET (polyethylene terephthalate)

and PU (polyurethane) and a deeply engineering Pseudomonas putida will metabolise the resulting

monomers P4SB contributes to the EU recycling targets which for PET must increase from 30

(2014) to 50 (2020) and for PU from 5 (2014) to 70 (2020)

The expectations of P4SB to maximise impact rely on the selection of a good business case ie PU

waste valorisation and the inclusion of different compatible commercial partners that cover the

value chain (Soprema ndash PU production Proteus ndash enzyme engineering Bacmine ndash synthetic biology

and Bioplastech ndash PHA production) The role of combined project partners and their collaboration

with industrial partner Bioplastech was shown as a case study leading to 1) basic research to

improve synthetic biology tools for key microorganisms for polymer production 2) access to

enzymes and enzyme technology for feedstock preparation 3) development of various organisms

and system models for bioprocess improvements and 4) novel downstream polymer recover

technologies



Coordinator Rheinisch-Westfaelische Technische Hochschule Aachen (Germany)

Website wwwP4SBeu

Topcapi

Thoroughly Optimised Production Chassis for

Advanced Pharmaceutical Ingredients

Topcapi is a Horizon 2020 project that will create actinomycete cell factories which can produce

commercially viable levels of the antibiotic GE2270 and of tetracycline derivatives The project will

use systems biology to optimise and engineer the metabolism of these strains for use in

established industrial processes based on actinomycete platforms Pathway engineering will

optimise the biosynthesis pathway for the target compounds allowing high efficiency synthesis

while minimising the production of side products The project will also develop generic microbial

chassis and systems and synthetic biology tools paving the way to further development of the bio-

economy through novel or improved bio-refinery processes



Coordinator The University of Manchester (United Kingdom)

Logo and website in progress

12

Chassy

Model-based Construction and Optimisation of Versatile Chassis

Yeast Strains for Production of Valuable Lipid and Aromatic

Compounds

Chassy is a multi-partner project that aims at delivering a suite of yeast strains that can serve as

versatile platforms for the production of high value oleochemicals and aromatic molecules This will

be achieved by integrating the knowledge gained from systems biology with the engineering tools

of synthetic biology to redesign metabolic pathways in the target yeast species These redesigned

strains will have optimised levels of product precursors and will serve as versatile chassis for

industrial exploitation

The project expects to boost technological innovation for European industries to keep their

leadership in the food feed fuel cosmetics and pharmaceutical industries The creation of a SME

stakeholder group will encourage growth and innovation in the European biotechnology sector by

ensuring that interested European SMEs are made aware of opportunities to commercially exploit

the knowledge technologies and chassis strains that are developed in the project



Coordinator University College Cork (Ireland)

Website httpschassyeu

Rafts4Biotech

Synthetic Bacterial Lipid Rafts to Optimise Industrial Bioprocesses

Rafts4Biotech will engineer two types of bacterial cells to generate synthetic bacterial lipid rafts to

confine industrial reactions protecting cells from undesirable metabolic interferences and in

consequence improving their efficiency for manufacturing processes This technology will be

virtually applicable to any microbial system and for all kind of industrially relevant reactions The

impact of Rafts4Biotech will be wide-ranging with applications envisaged in sectors such as the

pharmaceutical (generating microbial chassis capable of producing lipid-binding antibiotics in

industrial settings) cosmetics (increasing the efficiency of vitamins bioproduction) and that of

animal feed (cell factories capable of eliminating toxic pollutants from food and drinking sources)



Coordinator Centro Nacional de Biotecnologia (Spain)

Website in progress

13

32 Biotechnology-based industrial processes

DiViNe

Sustainable downstream processing of vaccines through

incorporation of nanobiotechnologies novel affinity ligands and

biomimetic membranes

DiViNe is a project based on an industrial consortium that aims at improving the downstream

process of vaccine production in order to reduce the cost of vaccines The general concept consists

in using affinity chromatography combining two major nanotechnology innovations (Nanofitinreg

ligands for affinity capture and Aquaporin Insidetrade membranes for fluid recycling) to develop an

integrated purification platform amenable to diverse heterogeneous types of vaccines

glycoconjugates protein antigens and viruses High yields are expected at affordable cost of goods

and with a sustainable approach to water recycling

One of the objectives of the DiViNe project is to obtain Nanofitins against the targets and evaluate

them in combination with a chromatographic support This part of the work involved first GSK for

provision of the first target then Affilogic for discovery and early characterisation of Nanofitins

binding to it and lastly Merck for immobilisation of the best Nanofitin candidates to

chromatographic resins This platform-approach from target to affinity material implemented

during the first 18-month period for one of the targets illustrates the custom platform that will be

available by the end of the DiViNe project for commercial service in the biopharmaceutical field at

large



Coordinator Instituto de Biologia Experimental e Tecnologica (Portugal)

Website wwwdivineprojecteu

nextBioPharmDSP

Next-generation biopharmaceutical downstream process

The aim of this project is to develop a continuous process for purifying bio-pharmaceuticals by

optimising and integrating different parts of the downstream process (DSP) since this part of the

manufacturing process represents a substantial overall cost and a bottleneck from the perspective

of efficient production The main objective of this project is to implement a fully integrated

manufacturing platform for biosimilar monoclonal antibodies based on continuous chromatography

in combination with different flow-through techniques based on disposable single-use techniques

for all unit operations of the DSP sequence concept together with incorporation of advanced

analytical tools

14

The project is run by a consortium that includes three large companies and three academic

partners and one SME The main benefits of the project are reduction of production costs and

efficiency improvement which will ultimately lead to expanded accessibility of patients to these

highly efficient drugs Another important aim is lowering the environmental footprint and moving to

more sustainable technologies nextBioPharmDSP has already submitted three publications and

filed two patents on advanced analytical tools and developed a prototype that will be tested in

2017



Coordinator Lek Farmacevtska Druzba DD (Slovenia)

Website wwwnextbiopharmdspeu

ROBOX

Expanding the industrial use of Robust Oxidative Biocatalysts for

the conversion and production of alcohols

ROBOX is an Innovation Action aimed at demonstrating the techno-economic viability of

biotransformations of four types of robust oxidative enzymes P450 monooxygenases (P450s)

Baeyer-Villiger monooxygenases (BVMOs) Alcohol dehydrogenases (ADHs) Alcohol oxidases

(AOXs) It will demonstrate 11 target reactions on large scale for these markets in order to prepare

them for plants up to commercial-scale

Efforts to maximise impact in ROBOX are focussed on several fronts 1) the innovations tackled

expand to processes products and platform technologies 2) the work covers industrially relevant

demonstration cases it uses representative minipilot plant scale for demonstrations it involves a

broad range of biooxidation enzyme classes and it aims at creating value of products with novel

properties 3) a balanced consortium of Industry SMEs and Academia is involved 4) the

exploitation of the technology first is planned within the consortium then dissemination of results

targets the academic and industrial communities so that replication of the successful technologies

can also take place outside the consortium Dissemination to the academic and industrial

communities is ensured through scientific publications in both peer reviewed and secondary

(industrial) journals Presentations have been given at scientific conferences (eg Biotrans and

Biocat) and events attended by process chemists (eg Scientific Update conferences) In addition

the consortium has also organised sessions at scientific conferences (in 2016 the 1st Aachen

Protein Engineering Symposium and the 5th International Conference on Novel Enzymes)

Exploitation of results of the demonstrations is planned by the end of the project especially if it

regards the production of a target molecule However exploitation of platform technologies such

as novel enzymes or enzyme kits can and will already be offered as products and services to the

broader chemical industry (outside the consortium) from the 3rd year on



Coordinator DSM Chemical Technology RampD BV (The Netherlands)

Website wwwh2020roboxeu

15

Carbazymes

Sustainable industrial processes based on a C-C bond-forming

enzyme platform

The CarbaZymes project will develop sustainable industrial processes based on a C-C bond-forming

enzyme platform This technology uses specific enzymes and intensive reaction development The

aim of the project is the implementation of a biocatalytic carboligation platform by making stable

diverse and efficient catalysts for new processes With inherent safety advantages over traditional

chemical methods this platform aspires to replace the current use of hazardous components for

the industrial scale manufacturing of products with high economic and societal value In particular

the focus is on the industrial production of important market-relevant pharma and bulk chemicals

including polymer precursors in an environmentally friendly mode

The project reported progress to date which includes the development of specialised enzyme

databases (using newly created algorithms) the characterisation of enzymes of interest the

construction of a Thermus strain (for protein engineering purposes) and the development of

biocatalytic process for scale-up

The project has already filed one patent application on fusion proteins for the enzymes sector and

is in the process of filing two more Carbazymes has engaged in education and training activities

producing an educational video (httpswwwyoutubecomplaylistlist=PLvpwIjZTs-

LjYqeOiYYqRWlegdihyjGgu) it will organise the conference sequel of Novel Enzymes 2018 and it

will co-organise the conference series BioTrans 20172019 It is expected that the project will have

a major positive influence on greening the European chemical industry contributing to a reduction

of its environmental impact by reducing emissions energy consumption and toxic waste



Coordinator Technische Universitaet Darmstadt (Germany)

Website wwwcarbazymescom

Volatile

Biowaste derived volatile fatty acid platform for biopolymers

bioactive compounds and chemical building blocks

Volatile is a new project that will recover volatile fatty acids from municipal and industrial bio-

waste treated by anaerobic digestion using membrane technology The volatile fatty acids will be

transformed via fermentation approaches into biopolymers single cell oil and omega-3 fatty acids

for the materials petrochemical and nutraceutical industries

Europe has a potential of 88 Mio ton of bio‐waste per annum and more than 14500 biogas plants

are installed in Europe These facilities could be transformed into building block providers (VFA) to

the fermentation industry Employment potential (in the next 15 years) is 1250‐2500 direct jobs

and 500‐1250 indirect jobs

16



Coordinator Tecnalia (Spain)

Website wwwvolatile-h2020eu

Falcon

Fuel And chemicals from Lignin through enzymatic and chemical

CONversions

Falcon aims at turning lignin-rich industrial waste from second generation biofuel plants into higher

value products which will include fuels for ships fuel additives and chemical building blocks The

adoption of the Falcon technology which is based on an enzymatic and mild chemical conversion of

the lignin waste at European scale by 2030 would create up to 9000 permanent and 20000

temporary jobs and additional revenue of 800M Euros



Coordinator CBS-KNAW Fungal Biodiversity Centre (The Netherlands)

Website in progress

Dafia

Biomacromolecules from municipal solid bio-waste fractions and

fish waste for high added value applications

Dafia aims at exploring conversion routes of municipal solid waste (MSW) from the fish processing

industries to obtain high added value products such as flame retardants food and feed barrier

coatings and chemical building blocks to produce polyamides and polyesters for a wide range of

industrial applications Selected value-chains and products will be explored based on the potential

commercial value and technical feasibility New microbial strains and cost-efficient processes for

conversion of feedstock fractions will be developed as well as enzymatic and chemical

modifications of components isolated from the feedstock or produced in microbial processes

Employment potential by 2025 is 670 direct jobs and 2000 indirect jobs



Coordinator AIMPLAS (Spain)

Website in progress

17

33 Innovative platform technologies

DD-DeCaF

Bioinformatics Services for Data-Driven Design of Cell Factories

and Communities

DD-DeCaF is a project based on data-driven design of cells and microbial communities for

applications ranging from human health to sustainable production of chemicals With advances in

synthetic biology genomes can now be edited at unprecedented speed allowing making multiple

changes to be made in the same genome at the same time

The project brings together leading academic partners from academia and industry addressing the

challenge of building a comprehensive design tool The academic partners will develop cutting edge

methods for using large scale data to design cell factories and communities for biotechnological

applications The SME partners will convert these advanced methods to software tools that can be

used by non-experts and to build intuitive visualisations of biological networks These tools will be

tested and applied to real world cell factory development projects by end-user partners The

project will take a series of concrete measures to maximise its impact Examples include active

dissemination of software tools participation in standardisation efforts and outreach activities in

the form of end-user training and workshops



Coordinator Technical University of Denmark (Denmark)

Website httpdd-decafeu

CanPathPro

Generation of the CanPath prototype-a platform for predictive

cancer pathway modelling

Omics technologies are generating complex molecular datasets that are exponentially increasing

the cancer knowledge base However the great molecular complexity and heterogeneity exhibited

by most cancers which is reflected in their omics characterisation necessitates a systems biology

approach for analysis and interpretation CanPathPro is developing and refining bioinformatic and

experimental tools for the evaluation and control of systems biology modelling predictions The

CanPathPro prototype - a combined experimental and systems biology platform - will allow users to

integrate private or public data sets to predict the activation status of individual pathways thus

enabling in silico identification of cancer signalling networks critical for tumour development as

well as the generation of hypotheses about biological systems which can be experimentally

validated

18

CanPathPro is set to have significant impacts on diverse areas from cancer research and

personalised medicine to drug discovery and development New innovative solutions for accessing

and exploiting datasets will be developed that will provide extensive capability to bridge e-

information from various application areas accelerating discovery and product development The

project will also bridge the gap from lab to market for SMEs Indeed two of the projectrsquos nine-

member consortium are SME specialists in industries related to medical research and with a strong

track record in commercialising scientific innovation They will develop a business and

commercialisation plan to show how companies could use the project outcomes to generate new

business and jobs



Coordinator Alacris Theranostics GmbH (Germany)

Website wwwcanpathproeu

Metafluidics

Advanced toolbox for rapid and cost-effective functional

metagenomics screening- microbiology meets microfluidics

Metafluidics is developing innovative tools by combining molecular tools microfluidic tools and

bioinformatics that will lead to novel enzymes for biosynthesis of therapeutic small molecules

green bioenergy conversion food chemistry and other medical and industrial applications

Metafluidics screens genome libraries to find relevant enzymes for the bioeconomy and develops

methods for high-throughput functional screening of metagenomes These tools will be used to

address user needs such as fighting antibiotic resistance pathogen detection food safety and

novel functional enzymes Indeed the results of Metafluidics can be linked to different societal

challenges and its products target different industrial sectors In addition the project aims to

contribute to standardisation in the field of metagenomics at European and international level and

will take a series for measures and actions to maximise its impact Examples include dissemination

and exploitation of project results data management and protection and communication and

outreach activities such as workshops and conferences



Coordinator Universidad Autonoma de Madrid (Spain)

Website httpwwwmetafluidicseu

19

Virus-X

Viral Metagenomics for Innovation Value

Virus-X addresses the unexplored territory of viral genomes It aims to exploit the viral biological

diversity of metagenomes of viruses in natural ecosystems and their encoded gene products It will

do so by sampling extreme biotopes as well as through sequence-based bioprospecting

methodologies combining bioinformatics gene annotation structural determination of proteins and

functional screening

The potential for innovation is enormous in consequence the project strives to have new enzymatic

products of viral origin bioinformatics tools improved structural biology services and molecular

applications in the market In order to maximise impact Virus-X has an Industrial Innovation

Board and an Intellectual Property Rights Instrument The industrial drive of the project is assured

by the involvement of five SME (Prokazyme AampA Biotechnology ArticZymes BioProdict SARomics

Biostructures)



Coordinator Prokazyme EHF (Iceland)

Website httpvirus-xeu

34 Cross-cutting biotechnology actions

Cobiotech

Cofund on biotechnologies

Involving 24 partners and one observer Cobiotech results from the merging and continuation of

three previous ERA-NETs ERASysApp ERA-IB and ERA SynBio Started at the end of 2016 the

project aims at 1) maximising synergies between current mechanisms of biotechnology research

funding in Europe 2) fostering the exchange of knowledge across borders 3) highlighting the

benefits of a bio-based economy for society and 4) maintaining and strengthening Europersquos position

in biotechnology The first call for proposals of Cobiotech contains topics on 1) Sustainable

production and conversion of different types of feedstocks and bioresources into value-added

products 2) New products value-added products and supply services and 3) Sustainable industrial

processes Proposals will use synthetic biology systems biology bioinformatics tools and

biotechnological approaches

Cobiotech expects to increase impact by bridging the gap to innovation an aim that will be pursued

through significant efforts in communication additional joint funding activities the establishment

20

of the European Biotechnology Hub and the development of a strategic research and innovation

agenda (SRIA)



Coordinator Project Management Juelich (Germany)

Website httpswwwcobiotecheu

Progress

Priorities for Addressing Opportunities and Gaps of Industrial

Biotechnology for an efficient use of funding resources

The overall aim of Progress is to support and accelerate the deployment of industrial biotechnology

(IB) by EU industry through identification of high-value opportunities and actions to address them

successfully The project will provide a comprehensive and dependable information base foster a

common vision for IB and elaborate a future scenario for IB in Europe providing strategic advice

for research industry and policy

In addition Progress will identify opportunities for collaboration in RampDampI between EU Member

States boosting the participation of smaller countries and propose actions to increase awareness

and incentives for those collaborations The project will also enhance understanding of the drivers

and barriers as regards valorisation of research via business applications



Coordinator Fraunhofer Institute for Systems and Innovation Research ISI (Germany)

Website wwwprogress-bioeu

35 SME Instrument

SO2SAFE

Enzymatic SO2 biosensor for rapid food safety monitoring

The SO2SAFE project has developed a miniaturised enzyme-based electrochemical biosensor that is

highly sensitive selective rapid and user friendly as regards the detection of sulphites added to

shrimps crabs and other crustaceans The project will scale up its manufacturing process targeting

all agro-food industries where sulphites are used as additives The scale-up process will optimise

production costs and increase production capacity SO2SAFE will also demonstrate to final users

the improved performance of the miniaturised biosensor The project has identified some barriers

to market the product whch are likely to arise because of the low acceptance of disruptive

technologies by the food industry due to its tendency to use only official detection methods In

21

order to increase the acceptability of the product by final users and regulatory authorities

SO2SAFE has requested support from the EC and the project is engaged in communication and

dissemination activities



Coordinator Biolan (Spain)

Website wwwbiolanmbcom

APEX

Advanced process economics through oxidoreductases

APEX coordinated by MetGen will bring MetZymereg enzyme solutions from small pilot scale pulp

and paper mills and bio-refinery to industrial production and commercial applications MetZymereg is

based on thermostable oxidoreductase enzymes with wide pH tolerance designed to break

recalcitrance of lignocellulosic biomass in harsh industrial conditions Small scale pilot studies done

together with large industrial customers have shown that these enzymes have the potential to

significantly improve the economic and environmental sustainability of paper chemicals and

biofuels

Through APEX MetGen will illustrate the full potential of MetZymereg the novel production system

Furthermore this will be done in an economically feasible way ndash changing the perception that

enzymatic solutions are expensive in comparison to mechanical or chemical ones and being a

strong competitor for these in the target markets MetGen aspires to be recognised as one of the

worldrsquos most significant enzyme developers and providers The APEX project makes it possible for

the company to bridge the gap between pilot and industrial scale and thus become financially

viable by the end of this project



Coordinator Metgen (Finland)

Website wwwmetgencomapex

4 CHALLENGES IN BIOTECHNOLOGY

41 Industryrsquos point of view

Speaker Joanna Dupont-Inglis European Association for Bioindustries EuropaBio

Ms Dupont-Inglis is the Director Industrial Biotechnology at the European Association for

Bioindustries (EuropaBio) Ms Dupont-Inglis stressed that the need to respect the environment

and the requirements of a growing population are both factors obliging stakeholders to follow the

principles of a circular economy and to be bio-based In consequence industrial biotechnology has

major potential ahead for example 31 Million tonnes of CO2 a year are currently avoided globally

as a result of industrial biotechnology ndashwhich is equivalent to emissions from 65 Million carsndash or

22

65 Million tonnes of CO2 emissions can be saved by 2030 by using enzymes in the detergents

textiles pulp and paper industries or 270 Million tonnes of agricultural residues in 2020 could be

refined into chemicals biomaterials and advanced bioethanol After offering reflections on the EUs

policy agenda jobs and growth the Energy Union the Circular economy and the COP Agreement

from Paris among others

Ms Dupont-Inglis focused on the current pros and cons for industrial biotechnology in the EU On

the positive side she noted the excellent knowledge base the Circular Economy package the

prospects for many sectors to become more sustainable and more competitive and the high

consumer appreciation of sustainability

Ms Dupont-Inglis presented data from a 2016 study undertaken by Europabio showing that the

current 486000 jobs in the industrial biotechnology value chain in the EU could go up to a range

between 900000 to 1500000 jobs by 2030 This expected employment could contribute between

euro575 and euro995 billion to the EU economy On the downside Ms Dupont-Inglis highlighted the

fragmented unpredictable and incoherent policy framework the difficulties to translate excellence

in research and innovation into bio-based commercialisation jobs and market growth the

limitations to attract and access investment for scaling up and the lack of clarity over feedstock

availability and sustainability Addressing these downsides would require coherent holistic and

supportive policies along the value chain of the bio-based industries measures to enable bio-

products to enter into the market investments combined with financing instruments and the

facilitated access to sustainable and equitable priced feedstocks

42 Academiarsquos point of view

Speaker Philippe Corvini European Federation of Biotechnology EFB

Philippe Corvini Vice-President of the European Federation of Biotechnology (EFB) represented the

voice of EFB representing about 30000 members He reported on major challenges bottlenecks

and opportunities in the six sections of the Federation microbial physiology applied biocatalysis

environmental biotechnology functional genomics polymer biotechnology and bioengineering and

bioprocessing Generically speaking

Mr Corvini stressed the need for major efforts for the optimal exploitation of big sets of data (eg

correct genome annotation) to better appraise the physiology of microorganisms and develop eco-

efficient bioprocesses He asserted that biotechnology can be competitive in comparison with

chemistry if attention is paid to the high step atom redox and conversion economies Beyond

2020 bio-hydrometallurgy and further bio-catalytical tools will be important to recover inorganics

and organics as well as CO2 from wasted resources such as by-products from industrial processes

Moreover taking on the challenge of ldquofood4allrdquo it is predictable that bacteria will be soil

conditioners for increased crop yields On the role of the EFB itself

Mr Corvini referred specifically to the opportunities in supporting the continuum between

fundamental research and commercial products and facilitating communication between industry

academia and other sectors Mr Corvini ended by stating that adequate training and educational

23

measures will be necessary to further develop novel converging technologies such as nano-

biotechnology and 3D-bioprinting

43 Standardisation of biological components and databases

Speaker Victor de Lorenzo Spanish National Research Council CSIC

Mr de Lorenzo Group Leader at CSIC Spain stressed the role of standards in fostering the

transition of contemporary gene-based Biotechnology from being a trial-and-error endeavour to

becoming an authentic branch of Engineering He argued that the inherent complexity of biological

systems and the lack of quantitative tradition in the field have largely curbed this endeavour thus

far Yet contemporary research in Life Sciences emphasises the need for standards not only to

manage omics data but also to increase reproducibility mdashthe lack of which plagues Biotechnology

and Biology in generalmdash and to provide the means to design purposeful biological systems in

depth Moreover as in the case of engineering adoption of standards could make a difference in

terms of the scalability and predictability of the endeavour Standards would allow decoupling

design from production from assembly from deployment

Standards would also provide opportunities for international collaboration as they allow different

communities to work together Immediate standardisation actions include rules for physical

composition of DNA sequences chassis tools for genome editing and languages to encode

workflows Other domains might be standardised with dedicated research (eg biological

metrology operative systems for bio-programming cells) and finally others will require a

considerable effort eg sorting out the rules that allow functional composition of biological

activities Despite difficulties these are worthy attempts as those who setadopt standards gain a

competitive edge in respect to those who do not

Mr De Lorenzo also connected the development of standards with industrial leadership the history

of technology has numerous examples of how those who developed well-grounded standards at the

right time gained a competitive edge in respect to others The current frontline research on

biological standards focuses on Metrology the National Institute of Standards and Technology

(NIST)-University of Stanford Joint Initiative for Metrology in Biology currently being in the lead He

concluded by highlighting that standards make the difference between genetic bricolage and

genetic engineering in earnest and that standardisation is one of the drivers of the bioeconomy

Finally he appealed not to let pass the opportunity of getting involved in the standardisation drive

running through biotechnology if we are to play a leading role in the onset of the 4th Industrial

Revolution

5 INTERNATIONAL DIMENSION OF BIOTECHNOLOGIES

51 Biotechnology in the USA

Speaker Theresa Good National Science Foundation NSF

Ms Theresa Good is the Deputy Division Director Molecular and Cellular Biosciences of the

National Science Foundation Ms Good first referred to the challenge of engineering biology that is

to harness the intrinsic capabilities of biological systems to manufacture products that are of

24

benefit to mankind She then went on to detail the research needs as being 1) understanding the

physical chemical and biological principles that govern life 2) improving tools techniques and

methodologies for prediction and design 3) enabling scaling-up usability interoperation safety

security and ethics 4) developing a future workforce based on interdisciplinary education and

training and 5) addressing challenges to ensure future US competitiveness in advanced

manufacturing

Ms Good outlined the funding history of Engineering Biology in the US over the years and

highlighted some of the success stories to date For example she mentioned the manufacture of

polymers-derived surfboards from algae oil and the use of microbial strains to produce the

precursor of artemisinin to fight malaria Ms Good explained that engineering biology today is a

time consuming and capital-intensive process where future investments are necessary to address

these issues She introduced the different US agencies investing in Engineering Biology mdashat the

levels of basic research research infrastructures and mission-driven researchmdash and associated

current investments with the research and technology development needs

Ms Good also pointed at some of the current opportunities for example the unique cross-

disciplinary ecosystem with strong industrial engagement that has changed how industry and

academia approach engineering biology as a result of ten years of funding the first synthetic

biology centre Among the challenges she pointed to the risk that the US could lose

competitiveness if working in isolation and that international investment is essential Other

challenges identified by Ms Good included the need to move engineering biology to higher

Technology Readiness Levels and the lingering issues related to public perception biosafety dual

use and ethics She concluded by summarising some of the many new and ongoing activities in

2016 such as the launch of the Engineering Biology Research Consortium and the Synthetic

Biology Standards Consortium

52 Biotechnology in China

Speaker Fengwu Bai Shangai Jiao Tong University and Asian Federation of Biotechnology

Mr Fengwu Bai is Distinguished Professor School of Life Sciences and Biotechnology at Shanghai

Jiao Tong University He introduced the programmes of the National Science Foundation of China

(Projects for Young Scholars General and Key projects InternationalRegional collaboration) plus

the National Key Research and Development Program of the Ministry of Science and Technology

(Fundamental RampD High-Tech RampD Innovations to upgrading traditional industries and

InternationalRegional collaboration) Mr Bai mentioned current challenges and stressed the need

for collaboration in the areas of agriculture (eg green pesticides) pharmaceuticals (eg vaccines)

industrial biotechnology (eg bulk commodities) and environment (eg pollution of water soil

air) He supported these needs with examples ie current dependency on foreign oil in China

(gt60 in 2015) and Europe (gt70 in 2014) and environmental pollution in north China

Mr Bai then focused on main areas of investment and interest in KET Biotechnology in China

synthetic and systems biology bioprocessing engineering as well as bio-refinery and bio-

manufacture He elaborated further based on a range of examples of current research work and its

outcomes use of systems biology and computational simulations to construct chassis for the

production of drugs materials and platform compounds fine tuning the compatibility of natural

25

enzymes via engineering to achieve higher catalytic efficiency Chinese participation in the

consortium to build the first yeast synthetic genome the creation of cellular machines to make

products such as terpenes steroids polyketides the commercialisation of ethanol fermented by

flocculating yeast and the over production of cellulases through batch-feeding of sugars Mr Bai

concluded by stating that the expectations of China in the area of industrial biotechnology are to

achieve in-country socio-economic development with the expectation of spill over into

neighbouring countries and ultimately marking China out as a global influencer in sustainable

development

53 Biotechnology in South Korea

Speaker Yoon-Mo Koo Center for Advanced Bioseparation and Asian Federation of Biotechnology

Mr Koo is the Director of the Center for Advanced Bioseparation Technology in South Korea He

structured his presentation around four axes the status of Korea in the 21st century biotechnology

in Korea its researchers and its industries Mr Koo began by framing Korea as the ldquoMiracle of the

Han Riverrdquo a 5000 year old country that is known worldwide for the modern success of strong

industries in electronics automobiles and petrochemicals among others He provided comparative

statistics (eg 2 of the area of Europe 10 of its population but 83 of its GDP per capita) and

supported these data on the efforts made in international competitiveness mdashfor which Korea ranks

22nd overall 7th in science and 11th in technologymdash plus public RampD investment mdash159 billion USD

and 44 in relation to its GDP (2nd worldwide after Israel)

Mr Koo explained that with the turn of the century a decreasing GDP growth triggered a

reorientation that led to a new focus being put on Biotechnology mdashbased on Korean traditions in

food and beverages medicine and cosmetics As a result investment in Biotechnology increased by

27 between 2010 and 2014 and representing 182 of the total investment in national RampD At

the same time Korea launched policies aimed at promoting biotechnologies and a plan to invest in

five major sectors life sciences health agro-fisheries and food industry and environment as well

as bio-convergence While higher investments are made in health and basic sciences significant

support is given to areas of industrial Biotechnology RampD such as the establishment of the

industrial ecosystem (biochemistry biotechnological convergence) development of clean materials

waste reduction and bioremediation plus energy recovery from waste and biomass Mr Koo

mentioned specific programmes of the Intelligent Synthetic Biology Center the development of

core technologies for converting gas into chemicals and the promotion of industrialisation

supporting innovative biotechnologies for promising new industries Other RampD efforts in industrial

biotechnologies include those in bioenergy (microalgae biorefinery new bulk biomass resources)

and bioconvergence (biosensors platform technologies for microorganisms engineering)

Data were also presented about supply and demand in the Korean bioindustry (exported 242 times

its imports in 2014) the weight of its manpower (researchproductionsales) and its level of

education the trend of investments and the evolution of cooperation (contracts licensing

manpower exchanges) at different development stages and with different types of organisation

Korean industries (Celltrion Samsung Biologics LG Life Science and others) reinvented themselves

moving into biotechnological sectors and universities research centres and companies engaged in

bioproduction

26

Mr Koo concluded with the following three points 1) industrial biotechnology biopharmaceuticals

medical and convergent biotechnologies are the main areas of current research 2) Korean

research would benefit from more international cooperation notably in industrial biotechnology and

cosmetics and 3) Korean industrial sectors face challenges arising from divergent interests of

academia and industry differences in scale between laboratories and pilot plants and the risks

inherent in the small capacity of Korean bioindustries

54 Biotechnology in Japan

Speaker Ken-ichi Yoshida Kobe University

Mr Yoshida is Professor at the Graduate School of Science Technology and Innovation of Kobe

University and Director of Kobe University Brussels European Centre He first introduced the new

biotechnology trends in Japan that respond to the parallel world trends in establishing a

bioeconomy with the objective that biotechnology contributes significantly to the market Mr

Yoshida drew attention to the smart-cell industry based on major technological innovations in three

areas 1) DNA sequencing (genomic information) 2) Information TechnologiesArtificial

Intelligence (bioinformatics) and 3) Genome editing (new functions) This mix of innovations

drives the design of smart-cells with desired functions Investments in these areas are made by the

Ministry of Economy Trade and Industry of Japan and the objectives are several fold a) healthy

longevity b) transformation of the structure of energy supply and reduction of environmental

impact c) availability of renewable resources and eco-friendly production (new biochemical

processes and production of rare fine chemicals) and d) food security

Mr Yoshida then focused on the Innovative Bio-production Centre in Kobe (iBioK) gathering Kobe

University and 14 private companies He provided an overview of major projects undertaken as

part of advanced interdisciplinary programmes aimed at generating continuous innovation with a

commercial focus These projects include the construction of cell factories for biorefinery mdash

breeding super microbial cells for direct production of fuels and chemicals from biomassmdash the

integration of technologies (molecular biology evolutionary engineering genome engineering) to

build a platform for industrial synthetic biology (design innovation gene cluster construction high-

throughput evaluation and machine learningmulti-omics data generation analysis and feedback)

Mr Yoshida described in detail the activities performed in each of the components of the platform

based on recent advances made by leading Japanese researchers (eg ldquonon-cleavingrdquo genome

editing and the automated construction of designed artificial gene clusters) He concluded by

highlighting advances in Japanese biotechnological research for biofuels as result of the

development of cell surface display systems the hidrolyzation of insoluble substrates including

lignocellulosic biomass direct ethanol production from hydrothermally pre-treated rice straw direct

production of isobutanol from cellulosic materials and construction of cell factories

27

6 PANEL DEBATE

The panel for the debate was composed of the following presenters

Mr Simon Charnock Prozomix Ltd

Mr Michael Lappe Qiagen Aarhus

Ms Laure Baillargeon DG GROW

Marco Rubinato EASME

Eleni Zika BBI PPP

The questions provided to the panel to facilitate the exchange of views were

1 What lessons learnt could help to ensure that the projects generate breakthrough exploitable results and to further improve their impact

2 Can you share an experience where cooperation (eg clustering of projects international cooperation) contributed to project success or enhanced impact

3 What are the barriers faced to reach the expected impact Are patenting and standards barriers or enablers

Mr Charnock who represented the view of an SME highlighted the importance of having a good

balance in the consortium with the right members from academia and industry in order to

maximise synergies Unfortunately in his opinion this was not always the case under FP7 projects

That said he commended the exploitation of Horizon 2020 projects Moreover he stressed that if

intellectual property (IP) issues arise these could negatively affect the flow of information within

the consortium and in consequence restrict or delay potential impacts

Mr Lappe explained that in large companies administrative inertia can slow down progress

Bringing together business goals with research investments is often be a challenge He agreed that

patenting could become a barrier

Ms Baillargeon stressed that consortia should have a clear view of their potential impacts from the

moment the proposal is prepared and that they should include detailed business plans for getting

the innovations to the market She also suggested engaging with communities outside the

consortium (stakeholders along the value chain) and involving experts on business development

and analysis for example through technology centres which provide ldquoecosystemsrdquo for innovation

Ms Baillargeon recommended gathering best practices from other areas such as ICT which could

be used as a reference

Mr Rubinato added that it is important to come up with ideas that will lead to novel products or

processes addressing market needs He mentioned that consortia that include SMEs tend to have

higher commitment to maximising impacts Mr Rubinato agreed with industry representatives that

patents are necessary but could also become barriers and he encouraged project consortia to find

the support to address these issues Based on his experience he confirmed that coaching on

business strategies is the most frequently requested service by project beneficiaries

Ms Zika said that BBI encourages the development of business models that integrate actors from

different areas fostering integration and cooperation She emphasised that projects should have

built-in work plans to transition from research to market On a separate note she raised concerns

about the gaps in education and training for the set of skills needed in industrial biotechnology

28

The debate was then opened to the floor The first part focused on issues related to the generation

of exploitable results and further improving their impact The following points summarise the

highlights of this discussion

1) the importance of expanding impact beyond the consortium identifying external stakeholder

groups that could be interested in developing the innovations further

2) the importance of resolving any internal reluctance on the part of commercial partners in the

consortium to share information outside due to intellectual property concerns - confidentiality

agreements are useful within the consortium but not with outsiders

3) the importance of obtaining early feedback from the market on the anticipated innovations by

including end-users and SMEs in the consortium intellectual property issues and deadlines

must also be addressed in the early stages and patents must be filed as soon as possible a

message was passed to the EU authorities on the need to work towards reducing patenting

costs

4) given the importance of dissemination and intellectual property for each innovation the right

solution must be found from the outset a list of potential innovations should be prepared

regularly revised and benchmarked against competitors

The debate evolved with discussions around the advantages of using any form of clustering and

cooperation in projects Ideas proposed where the organisation of workshops mdashsuch as the inter-

sectoral workshops organised under FP7mdash using platforms to promote clustering like COST-Actions

or participating in fora for industrial stakeholders (eg the European Forum for Industrial

Biotechnology) An opportunity to identify synergies was highlighted using the example of KET

Biotechnology Horizon 2020 projects and those funded by the BBI which focus on complementary

research themes

The paradox between the need for openness and clustering versus the importance of protecting

data and innovations was highlighted The need to publish by academic partners should be taken

into account while protection strategies must be adequately resolved by all stakeholders involved

Mention was made to the fact that a new commercial landscape where there is freedom of

information and open data is developing Keeping it all for yourself does not mean you have

more thus alternative innovation models such as free access to the results can always be

considered

29

7 CONCLUSIONS

The rapporteur Ms Garcia-Alonso made a brief summary of the conclusions to be taken away

from the workshop She commended the high quality of the presentations and the good overview

of project achievements given during the workshop

Many of the project presentations highlighted the importance of having varied and balanced

consortia with academic partners that can drive cutting edge research and commercial partners

that can guide the path to commercialisation The specialist knowledge of each partner provides

synergisms that pave the way towards a common goal Some projects emphasised the importance

of developing business plans early on and to include marketing and regulatory expertise to ensure

a smooth route to commercialisation Some of the commercial partners discussed the issues facing

industrial biotechnology such as practical implementation technology acceptance and limited

support from regulatory entities

The projects in more advanced stages shared experiences that facilitated their work thus seeding

ideas and best practices for other projects Many projects mentioned the role of collaboration to

enhance the prospects of finding new technologies new applications for those technologies and the

potential for developing new and useful products

One of the difficulties raised by many participants was the dilemma of communicating and

exchanging information openly while protecting new inventions and technologies However many

agreed that effective communication within the consortium and promoting synergies with other

projects could help innovation Communication with the public and public education in general

should improve the acceptance and understanding of biotechnology-based solutions

Ms Garcia-Alonso concluded her summary by pointing out that given the rapid progress of

industrial biotechnology standardisation and international cooperation were seen as important and

deserved particular attention

30

Appendix 1 Agenda

Agenda

EC-Workshop on Maximising the impact of KET Biotechnology

15 - 16 November 2016 Brussels Belgium

Venue Committee of the Regions (Room JDE 70) Rue Belliard 101 Brussels 1040 15 November 2016

1300-1315 Registration Chair Joseacute-Lorenzo Valleacutes Head of Unit DG RTDD2 1315-1320 Welcome address by the Chair 1320-1330 Policies and Incentives for Biotechnology in Horizon 2020

Peter DROumlLL Director RTDD 1330-1430 Cutting-edge biotechnologies

Synthetic Biology Mycosynvac Alain Blanchard INRAHubert Bernauer ATGBiosynthetics

Empowerputida Vitor Martin dos Santos WURElke Duwenig BASF P4SB Shane Kenny BioplastechAuxi Prieto CSIC Systems Biology Topcapi Eriko Takano University of Manchester Chassy John Morrissey University College Cork Rafts4Biotech Daniel Lopez CSIC

1430-1500 Coffee break 1500-1615 Biotechnology-based industrial processes Downstream processing DiViNe Olivier Kitten Affilogic

NextBioPharmDSP Gorazd Hribar Lek Pharmaceuticals

Biocatalysis Robox Martin Shcurmann DSMMarco Fraaije RUG CarbaZymes Simon Charnock Prozomix

Bioconversion of waste Volatile Thomas Dietrich Tecnalia Falcon Michael D Boot TUE Dafia Ferran Marti AIMPLAS

31

1615-1715 Innovative platform technologies Bioinformatics

DD-DeCaF Markus Herrgard DTU BiosustainSimao Soares Silicolife CanPathPro Bodo Lange Alacris

Metagenomics Metafluidics Aurelio Hidalgo UAMMichael Lappe Qiagen Aarhus Virus-X Arnthor Aevarsson Prokazyme

1715-1740 Cross-cutting biotechnology actions CoBioTech (ERA-NET) Petra Schulte Forschungszentrum Juumllich Progress (CSA) Sven Wydra Fraunhofer ISI 1740-1800 SME instrument

SO2SAFE Arrate Jaureguibeitia Biolan APEX Alex Michine MetGen Oy 1800-1900 Networking Drink

16 November 2016 Chair Joseacute-Lorenzo Valleacutes Head of Unit DG RTDD2 0900-0930 Challenges in Biotechnology 1) Industrys point of view Joanna Dupont EuropaBio

2) Academias point of view Philippe Corvini University of Applied Sciences and Arts Northwestern Switzerland and European Federation on Biotechnology

3) Standardisation of biological components and databases Victor de Lorenzo CSIC Spain

0930-1100 International dimension of biotechnologies

1) Biotechnology in the USA Theresa Good Deputy Division Director for Molecular

and Cellular Biosciences Directorate of Biological Sciences National Science Foundation

2) Biotechnology in China Fengwu Bai Distinguished Professor School of Life Sciences and Biotechnology Shanghai Jiao Tong University and Asian Federation of Biotechnology

3) Biotechnology in South Korea Yoon-Mo Koo Director of the Center for

Advanced Bioseparation Technology and Asian Federation of Biotechnology 4) Biotechnology in Japan Ken-ichi Yoshida Professor Graduate School of Science

Technology and Innovation of Kobe University and Director of Kobe University Brussels European Centre

1100 - 1130 Coffee break

1130 ndash 1230 Panel debate on Maximising the impact of KET Biotechnology Panelists - Simon Charnock from Prozomix Ltd (SMEs view) - Michael Lappe from Qiagen Aarhus (large companys view) - Laure Baillargeon (DG GROW) - Marco Rubinato (EASME)

- Eleni Zika (BBI JU) 1230 Conclusions and next steps Outcome of the workshop (by the Rapporteur) Outlook for the future (by the Chair)

32

Appendix 2 List of participants

Name Affiliation Project

AEligvarsson Arnthor Prokazyme Virus X

Blanchard Alain INRA MycoSynVac

Bai Fengwu Shanghai Jiao Tong University China and and Asian Federation of Biotechnology

Baillargeon Laure European Commission DG GROW

Benauer Hubert ATGBiosynthetics MycoSynVac

Boot Michael D Technical University Eindhoven Falcon

Charnock Simon Prozomix Carbazymes

Corvini Philippe European Federation of Biotechnology

de Bont Karen European Commission DG RTD

de Lorenzo Victor CSIC

de Vicente Carmen European Commission DG RTD

Dietrich Thomas Tecnalia Volatile

Doce Alberto European Commission DG RTD

Droumlll Peter European Commission DG RTD

Dupont-Inglis Joanna Europa-Bio

Duwenig Elke BASF EmPowerPutida

Fessner Wolf-Dieter Technical University Darmstadt Carbazymes

Fraaije Marco University of Groningen Robox

Fuentes Angel European Commission DG RTD

Garcia-Alonso Monica Estel Consult Ltd

Good Theresa National Science Foundation USA

Helmle Laszlo European Commission DG RTD

Herrgard Markus Technical University of Denmark DD-DeCaF

Hidalgo Aurelio Autonomous University of Madrid Metafluidics

Hribar Gorazd Lek Pharmaceuticals nextBioPharmDSP

Jaureguibeitia Arrate Biolan SO2SAFE

33

Kenny Shane Bioplastech P4SB

Kitten Olivier Affilogic DiViNe

Koo Yoon-Mo

Center for Advanced Bioseparation Technology and Asian Federation of Biotechnology South Korea

Lange Bodo Alacris Theranostics GmbH CanPathPro

Lappe Michael Qiagen Metafluidics

Loacutepez Daniel CSIC Rafts4Biotech

Marti Ferran AIMPLAS Dafia

Martin dos Santos Vitor Wageningen University EmPowerPutida

Michine Alex MetGen Oy APEX

Morrissey John University College Cork Chassy

OReagain Sean European Commission DG RTD

Prieto Auxi CSIC P4SB

Rubinato Marco EASME

Satzer Peter University of Natural Resources and Life Sciences Vienna nextBioPharmDSP

Schulte Petra Forschungszentrum Juumllich CoBioTech

Schurmann Martin DSM Robox

Soares Simao Silicolife DD-DeCaF

Sorg Tania Institut Clinique de la Souris ICS CanPathPro

Takano Eriko University of Manchester Topcapi

Valles Lorenzo European Commission DG RTD

Vouldis Ioannis European Commission DG RTD

Wydra Sven Fraunhofer ISI Progress

Yoshida Ken-ichi

Kobe University Japan and Kobe

University Brussels European Centre

Zika Eleni BBI-JU

34

Appendix 3 List of abbreviations

Abbreviation Definition

BBI-JU Bio-Based Industries ndash Joint Undertaking

CSA Coordination and Support Action

EASME Executive Agency for Small and Medium-sized Enterprises

EC European Commission

EFB European Federation of Biotechnology

ERA European Research Area

ETP European Technology Platform

EuropaBio European Association for Bioindustries

IA Innovation Action

IB Industrial Biotechnology

DG GROW Directorate-General Internal Market Industry Entrepreneurship and SMEs

FP Framework Programme

KETs Key Enabling Technologies

PPP Public Private Partnership

DG RTD Directorate-General Research and Innovation

SC Societal Challenge

SMEs Small and Medium-sized Enterprises

NIST National Institute of Standards and Technology

RIA Research and Innovation Action

How to obtain EU publications

Free publications

bull one copy

via EU Bookshop (httpbookshopeuropaeu)

bull more than one copy or postersmaps

from the European Unionrsquos representations (httpeceuropaeurepresent_enhtm)

from the delegations in non-EU countries (httpeeaseuropaeudelegationsindex_enhtm)

by contacting the Europe Direct service (httpeuropaeueuropedirectindex_enhtm) or

calling 00 800 6 7 8 9 10 11 (freephone number from anywhere in the EU) ()


Priced publications

bull via EU Bookshop (httpbookshopeuropaeu)

The European Commission organised a second EC-Workshop ldquoMaximising the Impact of KET

Biotechnologyrdquo in Brussels on 15-16 of November 2016 The event provided an opportunity for KET

Biotechnology funded project beneficiaries to show progress towards expected impacts


in their countries in view of potential cooperation with Europe The discussion of impact at the

workshop focused on 1) successes difficulties and good practices for maximising impact plus

common interests for collaboration 2) building capacities for a new generation of researchers 3)

need for supportive public policies for industrial biotechnology that would facilitate the transfer of

research products to the market and 4) identification of standardization of synthetic biology as a

driver of the fourth industrial revolution

Studies and reports

EUROPEAN COMMISSION


Directorate D mdash Industrial Technologies

Unit D2 mdash Advanced Manufacturing Systems and Biotechnologies

Contact Ioannis Vouldis

E-mail IoannisVouldiseceuropaeu

RTD-PUBLICATIONSeceuropaeu

European Commission

B-1049 Brussels

EUROPEAN COMMISSION


Biotechnology

Workshop Report


Rapporteur




LEGAL NOTICE








Freephone number ()

00 800 6 7 8 9 10 11


4

CONTENTS

EXECUTIVE SUMMARY 5


2 INTRODUCTION 6
















6 PANEL DEBATE 27

7 CONCLUSIONS 29




5

EXECUTIVE SUMMARY

























enhance success










in Europe




6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

EUROPEAN COMMISSION


Biotechnology

Workshop Report


Rapporteur




LEGAL NOTICE








Freephone number ()

00 800 6 7 8 9 10 11


4

CONTENTS

EXECUTIVE SUMMARY 5


2 INTRODUCTION 6
















6 PANEL DEBATE 27

7 CONCLUSIONS 29




5

EXECUTIVE SUMMARY

























enhance success










in Europe




6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

LEGAL NOTICE








Freephone number ()

00 800 6 7 8 9 10 11


4

CONTENTS

EXECUTIVE SUMMARY 5


2 INTRODUCTION 6
















6 PANEL DEBATE 27

7 CONCLUSIONS 29




5

EXECUTIVE SUMMARY

























enhance success










in Europe




6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

4

CONTENTS

EXECUTIVE SUMMARY 5


2 INTRODUCTION 6
















6 PANEL DEBATE 27

7 CONCLUSIONS 29




5

EXECUTIVE SUMMARY

























enhance success










in Europe




6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

5

EXECUTIVE SUMMARY

























enhance success










in Europe




6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

6









1 Introduction





6 Conclusions

2 INTRODUCTION

























7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

7
























closed it








materials (SC5)










8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

8










DD-DeCaF CanPathPro


Robox Carbazymes













9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

9










project(s) tba








Mycosynvac


animal vaccine







$9 billion by 2020


10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

10














EmPowerPutida






















11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

11

P4SB


Synthetic Biology















technologies




Website wwwP4SBeu

Topcapi















12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

12

Chassy



Compounds
















Rafts4Biotech













Website in progress

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

13


DiViNe


















large





nextBioPharmDSP









analytical tools

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

14







2017





ROBOX





























15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

15

Carbazymes


enzyme platform
























Volatile











16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

16





Falcon


CONversions









Website in progress

Dafia














Website in progress

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

17


DD-DeCaF


and Communities


















CanPathPro












validated

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

18









business and jobs





Metafluidics



















19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

19

Virus-X












Biostructures)






Cobiotech














20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

20


agenda (SRIA)





Progress
















35 SME Instrument

SO2SAFE










21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

21








APEX








biofuels





















22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

22







































23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

23
































Revolution







24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

24






manufacturing




































25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

25








development

































bioproduction

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

26




































27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

27

6 PANEL DEBATE






Eleni Zika BBI PPP































28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

28













costs










research themes







considered

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

29

7 CONCLUSIONS
























30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

30

Appendix 1 Agenda

Agenda












31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

31



















32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

32





























33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

33



Koo Yoon-Mo





















Yoshida Ken-ichi



Zika Eleni BBI-JU

34























Free publications

bull one copy








Priced publications












Studies and reports

34























Free publications

bull one copy








Priced publications












Studies and reports


Free publications

bull one copy








Priced publications












Studies and reports











Studies and reports

Documents

Maximising the impact of KET Biotechnology - Chassychassy.eu/media/2012/12/Maximising-Impact-of-KET-Biotechnology.pdf · The 2016 workshop “Maximising the impact of KET Biotechnology”